The passage of House of Representatives (HR) One, or the "One, Big, Beautiful Bill Act," brings official changes to students' ability to borrow federal loans. The federal Graduate Plus Loan will sunset, leaving medical students with unsubsidized loans as the primary federal borrowing option, capped at $50,000 per year and a total of $200,000 for professional degrees. Advocates argue the changes are needed to check tuition increases in higher education. Students may need to rely on private loans or institutional support to cover the remaining tuition or living expenses. Some of the challenges will be particularly daunting for Appalachia and West Virginia, a state entirely within the region. These new challenges present three realities to consider as well as three potential solutions. First, medical education tuition has been increasing substantially across the country, which has left in-state indebted students at public medical schools graduating with a median of approximately $200,000 to pay back. At the three medical schools in WV, tuition increases have aligned with national trends. However, as a second reality, specific to WV, there is a small applicant pool for the 392 open medical school seats in the state. Finally, Appalachia and WV have faced a perpetual provider shortage, particularly in rural areas, with many new doctors leaving the state and region soon after graduation. Despite these challenges, there are a few ways forward that may position the region well in the future. Medical schools may consider curbing tuition increases, cutting tuition, or ultimately subsidizing education for students with the greatest needs. Several institutions have already taken this route with support from philanthropists. Schools should also consider innovations to abridge the traditional four-year curriculum where possible and invest in accelerated tracks. Finally, health systems may need to rethink costly recruitment strategies and instead consider providing medical students with loans that are forgiven with years of service to the system.

Chronic low back pain and opioid use disorder often occur together, creating clinical situations that are complex and emotionally charged. Low back pain remains a common cause of disability and a major contributor to opioid prescribing. Although guidelines recommend exercise and other non-opioid treatments as first-line care, patients with co-occurring opioid use disorder frequently have limited access to these services and are more likely to receive escalating opioid doses instead. Stigma, fragmented systems, and regulatory pressures further complicate care and strain clinical encounters. Integrated approaches that combine medication treatment for opioid use disorder with behavioral and rehabilitative pain strategies offer a more practical way to address both conditions at once. Emphasizing function, safety, and clear communication can help move care forward, even when broader structural barriers remain.

Developmental disabilities and neurodevelopmental disorders (NDDs) are lifelong conditions that present complex medical challenges, particularly as individuals transition from pediatric to adult health care. Although these disorders typically manifest in cognitive impairment, motor dysfunction, seizures, and behavioral dysregulation, the degree of these symptoms can vary widely. This article introduces a structured clinical model known as the "Five Essential Concepts of Developmental Medicine," designed to guide the care of adults with NDDs. These concepts focus on understanding childhood-onset brain dysfunction, identifying the specific neurodevelopmental diagnosis, recognizing complications, assessing secondary consequences, and addressing syndrome-specific conditions. The model emphasizes the need for individualized care to prevent diagnostic overshadowing and ensure comprehensive health management. The authors advocate for integrated, multidisciplinary care systems, highlighting the critical importance of tailored screenings, early diagnosis, and proactive management to improve the quality of life for individuals with NDDs and developmental disabilities. This approach aims to bridge the gap in health care for this underserved population, addressing their unique medical needs and ensuring equitable access to care throughout the lifespan.

α-Gal syndrome (AGS), a tick bite-associated allergy to mammalian meat, affects an estimated 450,000 Americans, with the highest prevalence concentrated in the US South and Southeast. The lone star tick (Amblyomma americanum), ubiquitous across the region, transmits AGS sensitization, making reexposure nearly inevitable for outdoor workers and residents. Current management relies on dietary avoidance of mammalian products of an indeterminant length, a recommendation that is neither practical in a region where mammalian meat is central to cuisine and culture nor evidence based regarding duration or necessity. In the absence of treatment options, patients are turning to alternative interventions such as acupuncture protocols that lack validation from controlled trials. Meanwhile, oral immunotherapy has demonstrated safety and efficacy for other immunoglobulin E-mediated food allergies, and individual case reports suggest desensitization may be feasible for AGS syndrome. The US South, with its high disease burden, clinical expertise, and patient populations, is uniquely positioned to lead the rigorous phase 1 and phase 2 trials needed to develop evidence-based treatment alternatives. Without such research, patients have only dietary restriction as an evidence-based option and may seek purported treatments that lack rigorous validation.